Are pharma payments to doctors driving IVF overuse?
Australian researchers say the 'considerable' sums spent by companies on fertility clinicians and events may be responsible for unnecessary treatments.
The pharmaceutical industry has spent around $5.1m in the past three to seven years in payments to fertility doctors and on conference sponsorship, according to Australian research.
The “considerable” sum may have contributed to the overuse of assisted reproduction services, warn the University of Melbourne researchers.
The team analysed payments made by two companies that supply fertility medications to the assisted reproduction industry.
The sums had been reported to Medicines Australia under its transparency scheme.
